抗CXCL5/ENA-78抗体(Anti-CXCL5, Human, Goat-Poly antibody)

• 価格
• Product Details
• Applications and Data
• Related Product & Information

価格

目次に戻る

Product Details

Species Reactivity	Human
Label	Unconjugated
Immunogen	E. coli-derived recombinant human CXCL5/ENA-78Ala37-Asn114Accession # P42830
Source	Polyclonal Goat IgG
Purification	Protein A or G purified
Specificity	Detects CXCL5/ENA‑78 in direct ELISAs and Western blots.

目次に戻る

Applications and Data

	Recommended Concentration	Sample
Western Blot	1 µg/mL	Recombinant Human CXCL5/ENA‑78 (Catalog # 254-XB)
Neutralization	Measured by its ability to neutralize CXCL5/ENA‑78-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CXCR2. The Neutralization Dose (ND50) is typically 4-16 µg/mL in the presence of 30 ng/mL Recombinant Human CXCL5/ENA‑78.

Neutralization

Chemotaxis Induced by CXCL5/ENA‑78 and Neutral­ization by Human CXCL5/ENA‑78 Antibody. Recombinant Human CXCL5/ENA‑78 (Catalog # 254‑XB) chemo­attracts the BaF3 mouse pro‑B cell line transfected with human CXCR2 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CXCL5/ENA‑78 (30 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CXCL5/ENA‑78 Polyclonal Antibody (Catalog # AB-254-PB). The ND50 is typically 4-16 µg/mL.

目次に戻る

Related Product & Information

Entrez Gene IDs	6374 (Human)
Background	CXCL5/ENA-78
background_content	Background: CXCL5/ENA-78 CXCL5, also known as epithelial cell-derived-neutrophil-activating-peptide (ENA78), is an 8 kDa proinflammatory member of the CXC subfamily of chemokines. Its Glu-Leu-Arg (ELR) motif confers angiogenic properties and distinguishes it from ELR- CXC chemokines which are angiostatic. Human CXCL5 shares 57% amino acid (aa) sequence identity with mouse and rat CXCL5. Among other human ELR+ chemokines, it shares 77% aa sequence identity with CXCL6/GCP2 and 35%‑51% with CXCL1/GRO alpha, CXCL2/GRO beta, CXCL3/GRO gamma, CXCL7/NAP2, and CXCL8/IL8. Inflammatory stimulation upregulates CXCL5 production in multiple hematopoietic cell types, fibroblasts, endothelial cells, and vascular smooth muscle cells. In vivo, CXCL5 is elevated at sites of inflammation and pulmonary fibrosis where it promotes neutrophil infiltration and activation as well as angiogenesis. Its upregulation contributes to increased vascularization, tumor growth, and metastasis in many cancers. Full length CXCL5 (78 aa) is trimmed at the N-terminal end by Cathepsin G and chymotrypsin to ENA74 (74 aa) and ENA70 (70 aa), with the shortened forms showing increased potency relative to full length CXCL5. CXCL5 exerts its effects primarily through interactions with CXCR2. It also binds DARC, a decoy chemokine receptor which can limit CXCR2-mediated responses.

目次に戻る